Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2015-06-29

Clinical Trial Update: A Phase 1 Safety Study of LY2127399 in Combination With Bortezomib [Phase 1]

View source ↗

Summary

A completed Phase 1 safety study evaluating LY2127399 in combination with bortezomib for multiple myeloma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Bortezomib (bortezomib)
  • LY2127399 (dacetuzumab)

Snippet

Sponsor: Applied Molecular Evolution | Conditions: Multiple Myeloma | Phase 1 | Status: COMPLETED